The PRECIOUS-01 trial, sponsored by Radboud University Medical Center, is exploring a novel immunotherapeutic approach using PLGA nanoparticles to deliver iNKT cell agonists and tumor antigens for patients with NY-ESO-1-positive cancers. Given the prevalence of NY-ESO-1 expression in various malignancies (25-30% in advanced cancers), this asset targets a significant patient population with unmet medical needs. The trial's focus on safety, tolerability, and preliminary efficacy positions it strategically within the competitive landscape of immuno-oncology, where novel delivery systems and combination therapies are increasingly sought after. Successful outcomes could lead to further development and potential partnerships or licensing opportunities, particularly in the context of expanding immunotherapy portfolios.